NIAMS researchers collaborate to produce targeted immunosuppressant drug
Investigators at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Pfizer Global Research and Development and Stanford University have collaborated in studying a new immunosuppressant drug, CP-690,550, that may avoid some of the common side effects associated with other medications that curb the immune system. The new drug, discovered by Pfizer researchers, may be...NIAMS scientists find biochemical 'switch' directs muscle building
Scientists may soon be able to influence muscle formation more easily as a result of research conducted in the National Institute of Arthritis and Musculoskeletal and Skin... Diseases' Laboratory of Muscle Biology. The researchers there and at institutions in California and Italy have found that inhibitors of the enzyme deacetylase can switch the... p.... Osteoporosis, the major bone-weakening and fracture-causing disease which.has long been studied in. women, will now undergo major scrutiny in men with the award of a.seven-center, $23.8 million grant by. the National Institute of Arthritis and Musculoskeletal and Skin Diseases.(NIAMS) in partnership with the. National Institute on Aging and the National Cancer Institute at the....